On January 31, 2017, ProPhase Labs, Inc. filed a preliminary proxy statement soliciting proxies and urged the shareholders to vote for the proposals: (1) to approve the proposal to sell substantially all of the assets of the Company, which are comprised of the intellectual property and other assets relating to its Cold-EEZE brand and product line, to Meda Consumer Healthcare Inc. (MCH), and an affiliate of Mylan Inc. for cash, pursuant to the terms and conditions of that certain Asset Purchase Agreement, dated as of January 6, 2017, as amended, by and among the Company, MCH and Mylan Inc., and the other transactions contemplated thereby and (2) to approve the proposal to grant the persons named as proxies discretionary authority to adjourn the special meeting, if necessary, to solicit additional proxies to vote in favor of proposal no. 1.
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
PROPHASE LABS, INC. 
